Your session is about to expire
← Back to Search
Guadecitabine + Carboplatin for Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer treatment on both responsive and unresponsive patients. The treatment is a combination of two drugs, and patients will receive four cycles of it.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Guadecitabine and Carboplatin
Frequently Asked Questions
Is there a wide distribution of this clinical experiment in North America?
"This medical trial is running across 4 sites, including Milwaukee, Charlottesville and Muncie. To reduce travel demands for those participating in the study, it may be beneficial to opt for a site closer to you."
Has this treatment received the endorsement of federal health regulatory agencies?
"Our team has awarded a safety rating of 2 to this intervention, as it is still in its second phase and possesses evidence of being safe but not yet effective."
How many participants are being studied in this research project?
"At the moment, this trial is not recruiting any new participants. The study was initially posted on June 6th 2019 and had its most recent update on February 14th 2022. As an alternative, there are currently 1577 clinical trials actively enrolling small cell lung carcinoma patients and 1142 studies for this treatment seeking candidates."
Are new participants currently being accepted for this clinical trial?
"Recruiting for this clinical trial is not taking place at the moment; it was first published on June 6th, 2019 and last amended on February 14th 2022. However, there are currently 1577 active studies focusing on small cell lung carcinoma and 1142 actively admitting participants to treatment trials related to this condition."
To what extent has this therapeutic option been explored in prior research?
"The City of Hope Comprehensive Cancer Centre first conducted research on this therapeutic in 1997, leading to 1655 completed clinical trials. Currently, there are 1142 active studies happening primarily around Milwaukee, Wisconsin."
Share this study with friends
Copy Link
Messenger